Showing results (41-50 of 328) with videos related to

Sort By:
Pageof 33
Current Atherosclerosis Reports|February 9, 2022
Transintestinal cholesterol excretion in health and diseaseDamien Garçon, Jean-Matthieu Berger, Bertrand Cariou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2025
Versatile Functions of Hepatic Lipase in Lipoprotein MetabolismWieneke Dijk, Antoine Rimbert, Thibaud Sotin, et al.
Journal of Clinical Lipidology|August 6, 2025
Major lipoprotein(a) increase under IGF-1R inhibition in Graves' orbitopathy: A case reportMaxime Carpentier, Pierre-Olivier Bertho, Pierre Lebranchu, et al.
Clinical Therapeutics|August 18, 2015
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C LevelsEli M Roth, Maja Bujas-Bobanovic, Michael J Louie, et al.
Archives of Cardiovascular Diseases|December 19, 2022
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE studyPatrick Henry, Bertrand Cariou, Michel Farnier, et al.
International Journal of Cardiology|August 31, 2016
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsMichel Farnier, Daniel Gaudet, Velichka Valcheva, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2019
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN TrialsCyrus DeSouza, Bertrand Cariou, Satish Garg, et al.
Annales D'Endocrinologie|February 22, 2020
Improvement in arterial stiffness (pOpmètre®) after bariatric surgery. Results from a prospective studySamuel Frey, David Jacobi, Matthieu Pichelin, et al.
Annales D'Endocrinologie|August 22, 2018
Expert opinion on immunotherapy induced diabetesSarra Smati, Perrine Buffier, Benjamin Bouillet, et al.
Annales D'Endocrinologie|September 4, 2018
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitorsPerrine Buffier, Benjamin Bouillet, Sarra Smati, et al.
Pageof 33